Research progress of berberine in the treatment of polycystic ovary syndrome
10.3760/cma.j.cn101441-20211115-00503
- VernacularTitle:小檗碱在多囊卵巢综合征治疗中的研究进展
- Author:
Rui QU
1
;
Jingxuan WANG
1
;
Saijiao LI
1
Author Information
1. 武汉大学人民医院生殖医学中心 湖北省辅助生育与胚胎发育医学临床研究中心，武汉 430060
- Publication Type:Journal Article
- Keywords:
Polycystic ovary syndrome;
Berberine;
Insulin resistance;
Androgen;
Chronic inflammation
- From:
Chinese Journal of Reproduction and Contraception
2023;43(3):316-320
- CountryChina
- Language:Chinese
-
Abstract:
Polycystic ovary syndrome (PCOS) is one of the most common reproductive and endocrine diseases in women of childbearing age. The pathogenesis of PCOS is unclear and there is no radical cure at present. Its clinical manifestations include insulin resistance (IR), hyperinsulinemia, obesity, hyperandrogenemia (HA), increased cardiovascular risk, etc. Berberine (BBR) is an alkaloid extracted from coptis, with anti-inflammatory, antibacterial,decreasing blood lipids,treatment of IR and other multiple effects. In recent years, amounts of medical literatures have reported the therapeutic effects of BBR in PCOS, including improving hormone levels, chronic inflammation, IR, ovulation dysfunction and endometrial lesions, which shows a great prospect of clinical application. In this paper, we reviewed the research progress of BBR in the treatment of PCOS.
